Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRX-034
- Development stage
- Unknown
- Lead developer
- Primmune Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**PRX-034** is a small-molecule **TLR7 agonist** developed by Primmune Therapeutics for oncology and infectious diseases. It preferentially activates plasmacytoid dendritic cells (pDCs) to induce a robust interferon (IFN) response, including IFNα, with minimal proinflammatory cytokines like TNFα and IL-6, enabling systemic immune activation suitable for combination with immune checkpoint inhibitors (ICPIs). PRX-034 binds the guanosine site of TLR7, shows higher potency in human PBMCs (EC50 15 µM for pDC activation) than monkey cells, and is delivered systemically via oral prodrug PRTX007 after hepatic conversion.[1][3][9][11][14]
- Other names
- PRX034PRX-034PRX 034polvitolimodcompound 27compound27compound-27
02
Targets
TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on PRX-034.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRX-034.